Specialty drug costs are rising sharply, with 80% of novel drugs approved in 2023 classified as specialty and 75% of pipeline drugs in 2024 following suit.
At the same time, payers, manufacturers, and regulators are layering on new requirements for specialty pharmacies. These include dual accreditation, limited distribution networks, evolving 340B restrictions, and complex reporting requirements.
In this fact sheet, we discuss the five trends shaping the specialty pharmacy landscape. We also share five actions health systems can take as part of their specialty pharmacy strategies to maintain access , optimize patient outcomes, and preserve financial sustainability.
Additional contributors: Temima Saltzman, PharmD, Engagement Manager, Financial Transformation, and David Sekar, Engagement Manager, Financial Transformation
